Original research article| Volume 75, ISSUE 3, P199-203, March 2007

Download started.


The oral contraceptive containing 30 ��g of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study



      This nonrandomized study aimed to evaluate body weight and composition during the menstrual cycle and during oral contraception with 30 ��g of ethinylestradiol plus 3 mg of drospirenone (EE+DRSP).


      Multifrequency bioelectrical impedance analysis was carried out in 38 normally cycling women (mean age, 25.5 years) at baseline during the follicular phase (FP) and the luteal phase (LP) of the menstrual cycle and after three and six cycles of EE+DRSP to evaluate total body water (TBW), intracellular water (ICW), extracellular water (ECW), fat mass and fat-free mass. Body weight, waist-to-hip ratio, blood pressure and the plasma concentrations of electrolytes were also determined at each visit.


      TBW and ECW increased in the LP. During EE+DRSP, TBW and ECW were significantly lower than in the LP but similar to the values measured in the FP. No significant variations in ICW or in the other parameters were observed.


      EE+DRSP maintains the same concentrations in TBW and ECW observed in the FP. This effect is likely due to the antimineralocorticoid activity of DRSP, which counteracts the water retention elicited by estrogen.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Rosenberg M.J.
        • Waugh M.S.
        Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons.
        Am J Obstet Gynecol. 1998; 179: 577-582
        • Walters W.A.W.
        • Lim Y.L.
        Haemodynamic changes in women taking oral contraceptives.
        J Obstet Gynaecol Br Commonw. 1970; 77: 1088-1099
        • Crane M.G.
        • Harris J.J.
        Effect of oestrogens and gestagens on exchangeable sodium.
        in: Fregly M.J. Fregly M.S. Oral contraceptives and high blood pressure. Dolphin Press, Gainesvill (FL)1974: 159-169
        • Oelkers W.K.
        Effects of estrogens and progestogens on the renin���aldosterone system and blood pressure.
        Steroids. 1996; 61: 166-171
        • Oelkers W.K.
        • Helmerhorst F.M.
        • Wuttke W.
        • Heithecker R.
        Effect of an oral contraceptive containing drospirenone on the renin���angiotensin���aldosterone system in healthy female volunteers.
        Gynecol Endocrinol. 2000; 14: 204-213
        • Oelkers W.
        • Berger V.
        • Bolik A.
        • et al.
        Dihydrospirenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin���aldosterone system in normal women.
        J Clin Endocrinol Metab. 1991; 73: 837-842
        • Stachenfeld N.S.
        • DiPietro L.
        • Kokoszka C.A.
        • Silca C.
        • Keef D.L.
        • Nadel E.R.
        Physiological variability of fluid-regulation hormones in young women.
        J Appl Physiol. 1999; 86: 1092-1096
        • Elger W.
        • Beier S.
        • Pollow K.
        • et al.
        Conception and pharmacological profile of drospirenone.
        Steroids. 2003; 68: 891-905
        • Elger W.
        • Steinbeck H.
        • Schillinger E.
        • et al.
        Endocrine pharmacological profile of gestodene.
        in: Elstein E. Gestodene. Development of a new gestodene-containing low dose oral contraceptive. Parthenon Publishing, Carnforth (UK)1987: 19-33
        • Oddens B.J.
        Women's satisfaction with birth control: a population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural family planning, and sterilization among 1466 women.
        Contraception. 1999; 59: 277-286
        • Philibert D.
        • Bouchoux F.
        • Degryse M.
        • et al.
        The pharmacological profile of a novel norpregnane progestin (trimegestone).
        Gynecol Endocrinol. 1999; 13: 316-326
        • Krattenmacher R.
        Drospirenone: pharmacology and pharmacokinetics of a unique progestogen.
        Contraception. 2000; 62: 29-38
        • Foidart J.M.
        Added benefits of drospirenone for compliance.
        Climacteric. 2005; 8: 28-34
        • Apter D.
        • Borsos A.
        • Baumgartner W.
        • et al.
        Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms.
        Eur J Contracept Reprod Health Care. 2003; 8: 37-51
        • Mansour D.
        Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being.
        Eur J Contracept Reprod Health Care. 2002; 7: 35-41
        • Kyle U.G.
        • Bosaeus I.
        • De Lorenzo A.D.
        • et al.
        Bioelectrical impedance analysis���part II: utilization in clinical practice.
        Clin Nutr. 2004; 23: 1430-1453
        • Martinoli R.
        • Mohamed E.I.
        • Maiolo C.
        • et al.
        Total body water estimation using bioelectrical impedance: a meta-analysis of the data available in the literature.
        Acta Diabetol. 2003; 40: S203-S206
        • Gudivaka R.
        • Schoeller D.A.
        • Kushner R.F.
        • Bolt M.J.
        Single and multifrequency model for bioelectrical impedance analysis of body water compartments.
        J Appl Physiol. 1999; 87: 1087-1096
        • Stachenfeld N.S.
        • Silva C.
        • Keef D.L.
        • Kokoszka C.A.
        • Nadel E.R.
        Effects of oral contraceptives on body fluid regulation.
        J Appl Physiol. 1999; 87: 1016-1025
        • Reubinoff B.E.
        • Grubstein A.
        • Meirow D.
        • Berry E.
        • Schenker J.G.
        • Brzezinski A.
        Effects of low-dose estrogen oral contraceptives on weight, body composition, and fat distribution in young women.
        Fertil Steril. 1995; 63: 516-521
        • de Melo N.R.
        • Aldrighi J.M.
        • Faggion Jr, D.
        • et al.
        A prospective open-label study to evaluate the effects of the oral contraceptive Harmonet (gestodene75/EE20) on body fat.
        Contraception. 2004; 70: 65-71
        • Machado R.B.
        • Tachotti F.
        • Cavenague G.
        • Maia E.
        Effects of two different oral contraceptives on total body water: a randomized study.
        Contraception. 2006; 73: 344-347